ViiV HEALTHCARE ANNOUNCES FURTHER INITIATIVES TO IMPROVE ACCESS TO HIV MEDICATIONS FOR PEOPLE LIVING IN THE LEAST DEVELOPED COUNTRIES
- Voluntary licence policy extended to 69 countries, where 80% of all people with HIV live
- Generic companies offered royalty-free voluntary licences for all current ViiV Healthcare products and future pipeline
July, 2010, London, UK – Today ViiV Healthcare announced a new series of initiatives to support people living with HIV/AIDS in the poorest and most vulnerable countries. To address the evolving treatment needs in these countries, people living with HIV/AIDS will now be able to access the whole portfolio of ViiV Healthcare antiretroviral medicines, produced by generic companies. ViiV Healthcare is expanding the number of countries that this relates to, to include all least developed countries, all low income countries and all of sub-Saharan Africa – that is 80% of all people currently living with HIV.[i]
ViiV Healthcare is also making the groundbreaking step of making all patents available to generic manufacturers in these countries for all future pipeline developments, such as the novel integrase inhibitor jointly under development Shionogi - ViiVHealthcare, LLC.
“At present the numbers of people in the least developed countries moving onto second line therapy is very low compared to the developed world. However as more people have access to treatment, there is an increased need for second and third line treatment options once initial treatment failure occurs.” said Dr Dominique Limet, CEO of ViiV Healthcare “This is why we have taken steps to make our entire portfolio and our pipeline available through our royalty-free voluntary licensing and not-for-profit initiatives.”
Voluntary licences are granted by patent holders to allow a generic company to manufacture and sell versions of their products. ViiV Healthcare will now make these available, royalty free, to generic companies for all of their current portfolio, including the newer innovative products as well as future pipeline developments.
ViiVHealthcare acknowledges the contribution of Shire Pharmaceuticals Group plc, which has a Master Licence agreement with ViiVHealthcare, for products containing lamivudine; and of Shionogi co-developer of the integrase inhibitor with ViiVHealthcare that have also agreed to waive its rights to royalty payments in order to improve access for these products.
Other ViiV Healthcare initiatives
As announced at the time of launch, ViiV Healthcare also has a number of other key initiatives to support further access to therapies in the areas worst hit by the epidemic. They are:
- The Not for Profit Price commitment for our ARV portfolio to government and international procurement agencies such as the Global Fund for AIDS, Tuberculosis and Malaria and UNICEF – also expanding to these 69 countries today.
- The £10 million seed fund to support access to care and treatment for infants and children and to generate evidence for paediatric fixed dose combinations and formulations
- The Positive Action for Children Fund (PACF) and Positive Action programmes which support a community response to the epidemic. £3.6 million of new grants were announced by the PACF Independent Fund Advisory Board in Kenya supporting twelve projects in eight countries on 30th June 2010.
“At ViiV Healthcare we wanted to go one step further in addressing the HIV/AIDS crisis and supporting access for people living with HIV in the worst affected countries. As a company totally focussed and dedicated to tackling this epidemic we are passionately committed to thinking and acting differently and taking new steps to expand access.
At the occasion of my last trip to Kibera I was pleased to see that much more drugs were currently available to patients. But a lot more remains to be done as much more patients need or will soon need 2nd or 3rd generation products. This is why it is really important that we work as hard as we can to make those therapies available in these countries. It also showed methat the HIV agenda now needs to take into account not only doing what we can to make drugs available, but also supporting the whole health system, including medical professionals and the provision of health services such as diagnostic and laboratory tests.” commented Dr Dominique Limet, CEO of ViiV Healthcare.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established by GlaxoSmithKline (LSE: GSK.L) and Pfizer (NYSE: PFE) to deliver advances in treatment and care for people living with HIV. Our aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and then take a new approach to deliver effective and new HIV medicines as well as support communities affected by HIV.
GSK holds an 85 percent interest in the ViiV Healthcare and Pfizer holds 15 percent. GSK and Pfizer announced that they had agreed to form a new specialist HIV company on April 16, 2009. The transaction was completed on October 30, 2009. ViiV Healthcare launched on November 3, 2009.
For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.
Notes to editors
Which countries are in the 69 countries?
This decision applies to the Least Developed Countries (34 Africa, 14 Asia and Pacific, 1 Western Asia (Yemen), I Caribbean (Haiti)) – categorised on a variety of factors including poverty, structural weakness, landlocked, island state, limited capacity for growth, extreme vulnerability to external shocks and the Low Income Countries as defined by the World Bank[ii] not included by this list and all of sub-Saharan Africa.
The countries are:
Afghanistan, Angola, Bangladesh, Benin, Bhutan, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Cote d’Ivoire, Djibouti, DR Congo (Zaire), East Timor, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Gambia, Guinea, Guinea Bissau, Haiti, Kenya, Kiribati, Lao People’s DR, Lesotho, Liberia, Madagascar, Malawi, Maldives, Mali, Mauritania, Mauritius, Mozambique, Myanmar, Namibia, Nepal, Niger, Nigeria, North Korea, Republic Kyrgyz, Rwanda, Samoa, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Solomon Islands, Somalia, South Africa, Sudan, Swaziland, Tanzania, Tajikistan, Togo, Tuvalu, Uganda, Uzbekistan, Vanuatu, Vietnam, Yemen, Zambia, Zimbabwe
|UK Media enquiries:||Rebecca Hunt
(020) 8047 5502
|US Media enquiries:||Kevin Colgan
|(919) 483 2839
(919) 483 2839
|GSK European Analyst/Investor enquiries:||David Mawdsley
|(020) 8047 5564
(020) 8047 5543
(020) 8047 5503
|GSK US Analyst/ Investor enquiries:||Tom Curry
Jen Hill Baxter
|(215) 751 5419
(215) 751 7002
Brand names throughout this document are trademarks of the ViiV Healthcare group of companies.
980 Great West Road